Chosa Naoyuki, Ishisaki Akira
Division of Cellular Biosignal Sciences, Department of Biochemistry, Iwate Medical University, Yahaba, Iwate 028-3694, Japan.
Jpn Dent Sci Rev. 2018 Feb;54(1):37-44. doi: 10.1016/j.jdsr.2017.10.001. Epub 2017 Nov 9.
Mesenchymal stem cells (MSCs) retain the ability to self-renew and differentiate into mesenchymal cells. Therefore, human MSCs are suitable candidates for use in regenerative medicine and cell therapies. Upon activation by tissue damage, MSCs contribute to tissue repair through a multitude of processes such as self-renewal, migration, and differentiation. However, loss of self-renewal and multi-lineage differentiation potential occurs at a high rate during cell doubling. Effective MSC therapies require the establishment of new techniques that preserve MSC multipotency after lengthy cell expansions. Here, two novel mechanisms are described for maintenance of stemness in MSCs scrapie responsive gene 1 (SCRG1)/bone marrow stromal cell antigen-1 (BST1) ligand-receptor combination and cell-cell adhesion through N-cadherin. These two mechanisms findings provide a valuable tool for regenerative medicine and cell therapeutic methods that require the expansion of human MSCs while maintaining native stem cell potential.
间充质干细胞(MSCs)保留自我更新和分化为间充质细胞的能力。因此,人MSCs是再生医学和细胞疗法的合适候选者。在受到组织损伤激活后,MSCs通过自我更新、迁移和分化等多种过程促进组织修复。然而,在细胞倍增过程中,自我更新和多谱系分化潜能的丧失发生率很高。有效的MSCs治疗需要建立新技术,以在长时间细胞扩增后保持MSCs的多能性。这里描述了两种维持MSCs干性的新机制——瘙痒病反应基因1(SCRG1)/骨髓基质细胞抗原-1(BST1)配体-受体组合以及通过N-钙黏蛋白的细胞-细胞黏附。这两个机制的发现为再生医学和细胞治疗方法提供了一个有价值的工具,这些方法需要在保持天然干细胞潜能的同时扩增人MSCs。